KIDS Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Specialized Pediatric Orthopedic NicheA pediatric-only focus and dedicated global sales network differentiate OrthoPediatrics from adult-focused incumbents. Coverage of leading children’s hospitals and international markets can support surgeon adoption, recurring procedures, and durable expansion within a specialized market.
Strong Revenue Growth And Market AdoptionDouble-digit revenue growth, raised annual guidance, and strong Trauma & Deformity performance indicate continued adoption of the company’s products. Sustained procedure growth and new platform contributions should expand the revenue base and improve operating leverage over the next several quarters.
High Margins And Improving Operating PerformanceGross margins in the low-to-mid 70% range provide a strong economic foundation, while new-product mix and record adjusted EBITDA show improving operating performance. If mix benefits persist, the company has a clearer path to converting growth into stronger earnings and cash generation.
Bears Say
Persistent Operating And Net LossesThe company has not yet converted its strong gross profit into sustainable operating or net earnings. Persistent losses weaken returns on equity and leave profitability dependent on continued growth, margin gains, and expense discipline before the business can demonstrate durable earnings power.
Free Cash Flow Remains NegativePositive operating cash flow is encouraging, but negative free cash flow shows that reinvestment needs and capital spending still exceed internally generated cash. Continued set deployment and investment could require balance-sheet resources if the expected move to break-even is delayed.
Rising Operating Expense BaseHigher sales, marketing, and administrative spending reflects investment in clinic expansion and acquisitions, but it also raises the revenue required to achieve durable profitability. If expense growth continues ahead of gross-profit growth, operating leverage and the path to net income could remain constrained.
OrthoPediatrics News
KIDS FAQ
What was OrthoPediatrics Corp’s price range in the past 12 months?
Currently, no data Available
What is OrthoPediatrics Corp’s market cap?
OrthoPediatrics Corp’s market cap is $10.37B.
When is OrthoPediatrics Corp’s upcoming earnings report date?
OrthoPediatrics Corp’s upcoming earnings report date is Nov 03, 2026 which is in 45 days.
How were OrthoPediatrics Corp’s earnings last quarter?
OrthoPediatrics Corp released its earnings results on Aug 04, 2026. The company reported -$5.095 earnings per share for the quarter, beating the consensus estimate of -$5.129 by $0.034.
Is OrthoPediatrics Corp overvalued?
According to Wall Street analysts OrthoPediatrics Corp’s price is currently Undervalued.
Does OrthoPediatrics Corp pay dividends?
OrthoPediatrics Corp does not currently pay dividends.
What is OrthoPediatrics Corp’s EPS estimate?
OrthoPediatrics Corp’s EPS estimate is -3.82.
How many shares outstanding does OrthoPediatrics Corp have?
Currently, no data Available
What happened to OrthoPediatrics Corp’s price movement after its last earnings report?
OrthoPediatrics Corp reported an EPS of -$5.095 in its last earnings report, beating expectations of -$5.129. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of OrthoPediatrics Corp?
Currently, no hedge funds are holding shares in MX:KIDS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OrthoPediatrics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$471.47 (― Upside)
$471.47 (― Upside)
Blogger Sentiment
Neutral
MX:KIDS Sentiment 50%
Sector Average 62%
Sector Average 62%
Insider Transactions
Sold Shares
Worth $794.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.55%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
OrthoPediatrics Corp
OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products are meticulously crafted to be anatomically appropriate for treating children affected by orthopedic conditions across the United States and internationally. The company's diverse offerings span products for trauma and deformity correction, surgical systems for spinal deformities such as scoliosis, and solutions for sports medicine, among others. Their comprehensive product line features items like PediLoc, PediPlates, various cannulated screws, the PediFlex and PediNail systems, PediLoc tibia, advanced anterior cruciate ligament reconstruction systems, specialized locking cannulated blades and proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, the Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and the ApiFix Mid-C system. OrthoPediatrics Corp. primarily serves the pediatric orthopedic market, directly assisting pediatric orthopedic surgeons and caregivers. The company was founded in 2006 and maintains its headquarters in Warsaw, Indiana.
KIDS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial positive momentum: record revenue, record adjusted EBITDA, strong T&D and OPSB growth, material free cash flow improvement, and raised revenue guidance. Challenges were largely timing-related (zero 7D units, Brazil set timing) and temporary foreign exchange headwinds that widened non-GAAP loss per share. Management emphasized disciplined capital allocation and conservatism in guidance while highlighting a multi-year product 'super cycle' that should drive higher-margin, higher-ASP sales over time. On balance, positive operational and financial improvements outweigh the notable but mostly timing- and FX-driven lowlights.View all MX:KIDS earnings summaries